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Background: The COVID-19 pandemic has broadly disrupted biomedical treatment and research
including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and
evolving regulatory restrictions may not have allowed for systematic planning of how clinical and
research work may continue throughout the pandemic or be restarted as restrictions are abated. The
urgency to provide and develop NIBS as an intervention for diverse neurological and mental health
indications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts to
address the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS is
heightened including the potential to mitigate mental health consequences related to COVID-19.
Objective: To facilitate the re-establishment of access to NIBS clinical services and research operations
during the current COVID-19 pandemic and possible future outbreaks, we develop and discuss a
framework for balancing the importance of NIBS operations with safety considerations, while addressing
the needs of all stakeholders. We focus on Transcranial Magnetic Stimulation (TMS) and low intensity
transcranial Electrical Stimulation (tES) - including transcranial Direct Current Stimulation (tDCS) and
transcranial Alternating Current Stimulation (tACS).
Methods: The present consensus paper provides guidelines and good practices for managing and
reopening NIBS clinics and laboratories through the immediate and ongoing stages of COVID-19. The
document reﬂects the analysis of experts with domain-relevant expertise spanning NIBS technology,
clinical services, and basic and clinical research e with an international perspective. We outline regulatory aspects, human resources, NIBS optimization, as well as accommodations for speciﬁc
demographics.
Results: A model based on three phases (early COVID-19 impact, current practices, and future preparation) with an 11-step checklist (spanning removing or streamlining in-person protocols, incorporating
telemedicine, and addressing COVID-19-associated adverse events) is proposed. Recommendations on
implementing social distancing and sterilization of NIBS related equipment, speciﬁc considerations of
COVID-19 positive populations including mental health comorbidities, as well as considerations
regarding regulatory and human resource in the era of COVID-19 are outlined. We discuss COVID-19
considerations speciﬁcally for clinical (sub-)populations including pediatric, stroke, addiction, and the
elderly. Numerous case-examples across the world are described.
Conclusion: There is an evident, and in cases urgent, need to maintain NIBS operations through the
COVID-19 pandemic, including anticipating future pandemic waves and addressing effects of COVID-19
on brain and mind. The proposed robust and structured strategy aims to address the current and
anticipated future challenges while maintaining scientiﬁc rigor and managing risk.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords:
Non-invasive brain stimulation
COVID-19
Transcranial magnetic stimulation
Transcranial direct current stimulation
Transcranial alternating current stimulation
Transcranial electrical stimulation

Introduction
COVID-19 was ﬁrst recognized in December 2019 and within
months evolved into a global pandemic declared by the World
Health Organization (WHO) in March 2020. To avert its rapid
spread, country-speciﬁc restrictions have been introduced spanning strict social/physical distancing measures, stay-at-home orders and even lockdowns, workplace closings and furloughs/
layoffs, postponing of elective procedures in medical centers to
preserve medical resources, suspending many in-person medical
consultation and clinic visits, or substituting these face to face
consultations with remote interventions, e.g. telecommunications.

Measures to limit person-to-person contact affected institutions
and researchers applying non-invasive brain stimulation (NIBS)
operations. With the suddenness of COVID-19 emergence, operations at clinics and research centers administering NIBS were disrupted to varied degrees - from suspension of all activities, to
limiting new enrollment or abbreviation protocols, to incremental
accommodations - depending on regional restrictions and the nature of underling protocols (e.g. in-person treatment vs remote
treatment). The means of maintaining (and even expanding) access
to NIBS during the COVID-19 pandemic are strategically evolving.
Considering that NIBS is a unique non-pharmacological tool, forms
of which have been successfully established for treatment of a wide
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range of neurological and psychiatric disorders [1e7], often on
moderately or even severely impaired patients unresponsive to
conventional therapies [8,9], the reestablishment of NIBS operations in the current era of COVID-19 pandemic as well as through
future epidemics is of paramount importance.
Moreover, a further wave of mental health issues following this
ﬁrst outbreak of this virus is anticipated [10,11]. Forms of NIBS are
broadly applied and trials for mental health indications; thus, hold
the potential to mitigate the psychological after-effects or comorbidities of the pandemic. This ampliﬁes the urgent need for a
roadmap of how to resume NIBS-based clinical and research activities in the face of the COVID-19 and also future pandemics.
This expert consensus paper aims to outline processes that
could facilitate rapid, prudent, and coordinated re-establishment of
operations at institutions providing NIBS treatments or using NIBS
in research. We speciﬁcally focus on low intensity transcranial
electrical stimulation (tES; encompassing transcranial direct current stimulation [tDCS], transcranial alternating current stimulation [tACS], transcranial random noise stimulation [tRNS]) and
transcranial magnetic stimulation (TMS). However, our recommendations may be adapted to support the reestablishment of a
broad range of device-based interventions. A session of the NYC
Neuromodulation 2020 Online Conference (20e22 April 2020) was
dedicated to sharing experiences of NIBS researchers all over the
world which inspired the plan to synthesize these opinions in the
present document. Along with general guidelines and checklists,
we provide an overview on the different strategies that have been
introduced to mitigate the spread of the virus in NIBS procedures
and NIBS laboratories. Additionally, we highlight new opportunities
for NIBS regarding the current situation and discuss possible directions of research that could be taken considering the expected
development of COVID-19-related diseases and disorders. The
considerations presented here not only reﬂect the COVID-19 crisis
but also prepares the NIBS community for potential future epidemics or pandemics.
In general, steps taken to support NIBS operations under any
epidemic/pandemic conditions may span (a) reduction of unnecessary contact by judiciously removing protocol steps or transition
to telemedicine approaches (which may include the intervention
itself); (b) optimization of all at-center protocols based on sanitization (section 6.1), physical distancing (section 6.2), and streamlining procedures; (c) addition of protocols to manage risk such as
COVID-19 or related symptom screening (section 6.3) or steps to
support personnel affected by COVID-19 medically or professionally (section 5). These overarching principles apply with varied
weights to the 3 phases of COVID-19 response (section 4) and are
systematized through detailed guidance (section 4, section 5, section 6, section 9), our checklist (section 3.4), case examples (section
2, section 8) and consideration for speciﬁc clinical populations
(section 7).
Results from survey international accommodations in brain
stimulation labs/clinics to COVID-19
While strategies for the use of NIBS as a unique therapeutic tool
through the COVID-19 crisis are currently developing, in the immediate aftermath of COVID-19 emergency many clinical trials and
experiments involving neuromodulation around the world were
severely disrupted or suspended - with the exception of those that
employing remote at home tDCS treatments. In many cases,
research activities were diverted to writing, reviewing and
analyzing data remotely. Onsite clinical services were disrupted, in
some cases with services limited to teleconsultations. Following
initial disruption, several on-site services began to implement
remediation measures (section 8, section 9). Clinical services and

trials based around remote at-home tDCS through telemedicine
were generally able to proceed with minimal accommodations
(section 8, section 9). This section focuses on the immediate
response as reﬂected in the survey of NIBS centers.
The survey addressing the impact of the COVID-19 pandemic
was sent to institutions applying NIBS (research laboratories and
NIBS clinics) across the world. Replies were received from 29 institutions representing 17 countries. These responses thus reﬂect
the “situation on the ground” at the time of assessment with
ongoing remediation methods addressed later in this paper. Mainly
depending on the national and local restrictions in response to the
COVID-19 outbreak and the nature of protocols (e.g. type of technology, trial stage, clinical population), there were substantial discrepancies in the extent to which neuromodulation operations
were disrupted.
In February, preclinical and clinical research activities were
interrupted in China and Iran. In Europe, the restrictions imposed
by governments were implemented in an uncoordinated fashion; in
Italy, Portugal, Denmark, the United Kingdom and the United
States, restrictions were applied to clinic services and research labs
beginning in the ﬁrst half of March, while in Germany, Austria and
Belgium, restrictions were applied in the second half of March.
Switzerland and Brazil closed their labs in mid-March. Later, between the end of March and the beginning of April, clinics and
research activities were suspended and labs were closed also in
Canada, Russia, India, Australia, and Japan.
Globally, restrictions regarding hospitals often involved the
interruption of all non-emergency services and the re-organization
of routine activity focusing on handling COVID-19-related conditions. For many clinics where TMS and tES are used as treatment
tools or involved in clinical research protocols, restrictions led to
the suspension of non-urgent inpatient and outpatient services as
well as all in-person activities. In some clinics, staff members have
worked in rotation to minimize infection and provide only essential
services. In Italy and the United Kingdom even home-based neuromodulation protocols were not immediately approved or feasible
(Table 1).
Examples of protocols without substantial disruption include
the United States New York University (NYU) clinic and the
Australia Black Dog Institute in Sydney using remote at-home tDCS
treatments, which were largely able to continue operations with
moderate accommodations and have even met an increased demand. Several centers providing in-patient NIBS treatment maintained at least some services, in the US including Wake Forest
(North Carolina) and Medical University of South Carolina (MUSC),
to help dampen the potential surge in psychiatric symptoms and
illness resulting from the pandemic. Similarly, in Belgium at Ghent
University COVID-19 sub-wards were established in the psychiatric
clinic for the admissions of potential infected psychiatric patients.
TMS has continued to be provided in both outpatient and inpatient
programs in Australia although not in research protocols. At Ghent
University in Belgium, electroconvulsive therapy (ECT) has been
allowed only in selected cases depending on severity. The International Society for ECT and Neurostimulation published guidance
on ECT during COVID-19 [12].
With limited exceptions, the restrictions limiting the routine
and non-urgent clinical services and ceasing in-person activities
have severely affected clinical research. Despite the guidance
offered by agencies like the Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) on how to manage
clinical trials, clinical studies as well as single-center/multi-center
trials are being impacted by the COVID-19 pandemic. In the immediate aftermath of COVID-19, research labs all over the world
have been instructed to limit or stop most neuromodulation
research that had direct person-to-person contact and was deemed
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non-essential. The timing of the closures varied, as well as the
extent to which research was halted. Survey respondents report
additional challenges arising from social/physical distancing measures, site closures, travel limitations for staff members and patients, interruption of suppliers’ delivery, and considerations if
personnel or subjects might be infected with the new coronavirus.
Moreover, difﬁculties in meeting the required protocol-procedures,
including the follow-up visits and laboratory/diagnostic testing
resulted in a loss of data from ongoing trials, or in a delayed data
acquisition, will continue until centers fully reopen and likely
beyond (Table 2).
Based on our survey, all other institutions stopped the enrollment of new subjects. In some cases, patient treatment studies
were allowed to remain open to ﬁnish currently enrolled individuals, in other cases, institutions required investigators to
determine if their research studies were addressing essential needs
and disruption of the intervention would lead to irreparable harm.
It is possible that for some studies, new participants will need to be
enrolled to compensate for these losses, which was not budgeted
for across grants.
Even in early phases of COVID-19 responses, some centers
report adapting NIBS clinical trial protocols to minimize in-person
contact. Trials with remote home-based neuromodulation (tDCS
and tACS) have largely continued, in some cases received updated
approvals allowing for remote consenting (e-consent) and enrollment of new patients. For trials with in-center treatments, protocols are being implemented to allow for remote consenting, the
remote collection of clinical data and the conduct of online cognitive tests, allowing some aspects of brain stimulation trials to
continue even without home-based treatments.
Respondents to the survey reported teleworking is a central
component of the overall response to the COVID-19 pandemic.
While a challenge to the ‘normal’ culture way of working, telecollaboration could represent an unexpected opportunity for researchers to re-analyze collected data, acquire new analysis and
methods skills, design new experiments, pre-register scientiﬁc reports and brainstorm new ideas and projects. General tele-work
practices and routines have also been introduced across NIBS
centers to enable the remote working teams to maintain productivity, while monitoring and supporting the well-being, education,
and professional development of staff (see section 5). For example,
early career scientists and students concerned with the degree
progress should, as appropriate, be offered additional support by
adapting progress requirements (e.g. 3 months extensions concerning thesis submission deadlines) and providing them opportunities for online networking. Several respondents to our survey
highlighted the opportunity to learn new skills online (through
webinars, online lab meetings with guest speakers and online
conferences). Respondents are thus positive that the NIBS community could beneﬁt from tele-work intellectual activities developed in the pandemic period (e.g. online conferences, papers,
experimental designs, teaching materials, etc.) and the establishment of tele-communication tools should serve the NIBS community even beyond the pandemic period (e.g. project tracking and
updates, new collaborations).
At present, the NIBS community is in the process of preparing
for a return to either partial or full operational status in the
coming months. While institutional regulations for restarting inperson activities will vary, institutions surveyed consistently reported implementation of personal protective equipment (PPE)
standards, social distancing approaches, plans to convert the
consent process and assessments to tele-/video/online administration where possible, as well as sanitization procedures. A
number of labs also indicated plans for COVID-19 testing and facilities modiﬁcation to improve ventilation and social distancing
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procedures. At present a majority of sites surveyed do not have a
deﬁnitive restart date. While the future is uncertain, labs and
clinics are preparing for eventual return to service with an eye
toward implementation of plans to not only mitigate disruptions
from the COVID-19 emergency, but also methods that will allow
NIBS clinical and research services to weather future outbreaks of
COVID-19 or similar events.

Response to COVID-19 pandemic in NIBS labs/clinics: past,
current, future
A 3-phase model can describe responses to the COVID-19
pandemic in NIBS laboratories/clinics across the world, encompassing the immediate (Phase 0) to the COVID-19 emergency, the
current (Phase 1) state of strategic responses within evolving
COVID-19 restrictions (e.g. stay-at-home mandates), and planned
activities (Phase 2) to optimize productivity through the COVID-19
pandemic, through potential future outbreaks, and the prolonged
return to normal activities.

Phase 0: past measures in immediate response to stay-at-home
mandates from COVID-19
In almost all cases, the rate and scale of impact from the initial
COVID-19 outbreak created exigent circumstances that mandated
rapid decisions. This commonly included cessation of all nonessential in-person research activities. However, institutional
consideration was given in some cases for in-progress neuromodulation studies that involve the application of interventions
addressing diagnoses such as depression, with some studies
deemed essential and allowed to continue ongoing interventions
with strict adherence to PPE for both researchers and participants.
This determination was made by individual institutions with signiﬁcant variability across sites. In response to stay-at-home mandates, entire study teams were faced with moving all activities to
remote/tele continuation. For those involved in studies deemed
“essential,” structured plans to allow study team members in labs/
clinics and access to appropriate PPE were required. In addition,
studies either already designed for remote administration of assessments and/or interventions were allowed to continue, with
either minor or no modiﬁcation to existing protocols.
In some cases, studies were able to modify their existing protocols to continue research efforts on a fully remote basis using
tele-/online/video assessments or at-home brain stimulation procedures. However, many studies are incompatible with remote
continuation and were required to stop. For those faced with
remote/telework, documentation, reports of activity, approvals,
updates, online audits, online analysis, dissemination of results
through manuscript development, online conferences and study
team virtual meetings represented transitions requiring minimal
effort to implement. However, for those requiring access to
specialized hardware, specially protected data, or software, as a few
examples, housed within the workplace, this transition either
proved difﬁcult or resulted in work stoppage. Regardless, an
important element of the initial and ongoing response to COVID-19
across ongoing studies involved communication with all participants currently enrolled in ongoing studies to provide information
regarding how their participation in the study would be impacted
by stay-at-home mandates, as well as providing additional information for available local resources to address potential concerns
for their welfare and well-being during the outbreak (e.g. telemental health services, community assistance programs, etc.).

Name of the
institution

Start date of
restrictions

(Planned) date of
easing the
restrictions

Restrictions

Phase 0

Phase 1

Phase 2

Australia

Monash University
and Epworth
Healthcare

Beginning of April

To be decided,
returning to
campus is allowed
after June 1, 2020

None mentioned

Implementation of
teleconsultation

Belgium

Ghent University

March 17, 2020

May 4 or May 11,
2020

 Interruption of VNS and DBS
implantation
 Mental deteriorations in
some patients
 ECT capacity is reduced

 Teleconference
contacts,
phone calls, or face to face
contact (respecting the safety
guidelines)

Screening system developed
Screening remotely and inperson
Measuring body temperatures
Basic hygiene precautions*
 To be decided

India

Kasturba Medical
College, Manipal
Academy of Higher
Education
Gallimberti &
Partners (addiction
clinic)

March 23, 2020

Not speciﬁed

 Patients and
lockdown

under

 Implementation
of
teleconsultation for the followup of old patients

 Basic hygiene precautions*

March 9, 2020

May 18, 2020

 Inpatient and outpatient
treatment services are still
allowed
 Assessments are done via
telehealth
 COVID-19 sub-wards
 Non-urgent treatments and
ambulatory consultation
suspended
 rTMS maintenance is allowed
 ECT is allowed based on
severity
 Interruption
of
nonemergency services
 Rotating schedules to provide
essential services
 Interruption
of
clinical
protocols
 Only COVID-19 free patients
are admitted

 Data loss from ongoing
studies
 Increase of psychological
distress in addicted patients

 Implementation
of
teleconsultations (for
psychological and medical
support)

 Home-based protocols are
not approved yet

 PPE or transparent face
shields
 Rescheduling patients (only
one at a time)
 Measuring the temperature
of patients
 PPE or transparent face
shields
 Rescheduling patients (only
one at a time)
 Measuring the temperature
of patients
 To be decided

Italy

staff

Italy

IRCCS Santa Lucia
Foundation

March 9, 2020

May 18, 2020

 Interruption
protocols

Russia

National Medical
Research Center for
Psychiatry and
Neurology, St.Petersburg
Institute of
Cognitive
Neuroscience,
University College
London

March 26, 2020

Approximately
mid-May 2020

 Interruption of all clinical
activities

 None mentioned

 Teleconsultations for some
patients

March 6, 2020

To be decided,
maybe January
2021

 Interruption of care services
for community-based
aphasic stroke patients
 Interruption
of
remote
outpatient and treatment
services
 Interruption of all inpatient
and outpatient visits
 No visitors allowed in the
hospital

 Redeployment of clinical staff
to other units

 Teleconsultation (mainly for
advising families)

 PPE
 Home-based tDCS
 Shift schedules for staff
members
 Social distancing measures

 Interruption
activities

 Implementation
teleconsultation

 Questionnaire or checklist to
assess COVID-19 risk
 Testing for COVID-19
 PPE
 Remote or home stimulation
 Continue treatments and
enroll new patients remotely
 Follow
institutional
guidelines for infection
control for any onsite new
patient evaluations

United Kingdom

MA, USA

Beth Israel
Deaconess Medical
Center and Baystate
Medical Center

March 20, 2020

May 18, 2020

NY, USA

NYU Langone
Health, New York
NY

March 10, 2020

Late May 2020

of

clinical

 Interruption of all outpatient
visits

of

research

 Redeployed therapy staff to
work remotely
 Continued all ongoing tDCS
treatments using virtual
visits through the
institution’s telemedicine
platform

of

 Continue treatments and
enroll new patients to
service remotely
 Protocol for sanitation of
equipment, including
shipments (incoming and
outgoing) of equipment to
patients
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Country
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Table 1
COVID-19 and International Accommodations in Brain Stimulation Clinic Setting.
Survey data were collected from April 30, 2020 to May 6, 2020. To date, data on 9 institutes have been collected from 7 countries. Phase 0 refers to the challenges that affected clinical activities with respect to COVID-19. Phase 1
refers to the activities that have been implemented in response to the pandemic. Phase 2 refers to the precautions planned or already implemented during the reopening of NIBS clinics.

rTMS: repetitive transcranial magnetic stimulation; ECT: electroconvulsive therapy; tDCS: transcranial direct current stimulation; VNS: vagus nerve stimulation; DBS: deep brain stimulation; PPE: personal protective equipment.
basic hygiene precautions*: PPE, sanitization, social distancing.

 Approved for new patient
enrollment in service as
telemedicine provision

 Alternating
remote
and
onsite schedules for staff
members
 Social distancing measures
for clinical staff return to
onsite
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Phase 1: current response
During the COVID-19-related stay-at-home mandate, critical
consideration must be given to re-integration strategies and approaches for restarting studies and trials. The timing and details of
re-integration procedures will vary signiﬁcantly across institutions,
as did study stoppage and stay-at-home procedures. Nonetheless,
brain stimulation teams can begin planning for potential iterations
of re-integration procedures. At present, commonly discussed
strategies across institutions include a tiered return to institutions
for study teams, potential split shifts for study team members to
cover study activities, PPE for all participants and study staff,
COVID-19 infection or antibody testing procedures, body temperature assessment of all staff and participants, redesign of lab procedures/space to minimize person-to-person contact, new facility
and equipment sanitization procedures, among others (see also
below, section 6). While institutional procedures will vary,
advanced planning for how these procedures will impact study
continuation is important. In addition, study teams will be faced
with a backlog of participants that either missed planned follow-up
visits or have upcoming follow-up visits, as well as a need to replace
participants whose intervention schedules were interrupted by
stay-at-home mandates. Study teams will likely be strained to
perform all needed activities for study continuation upon return.
Advanced planning for prioritization of study activities will be
important for an efﬁcient transition back to in-person activity.
Phase 2: future response to COVID-19 and subsequent outbreaks
We are also faced with the uncertain possibility of one or more
recurrent waves of COVID-19 and similar epidemic/pandemic outbreaks in the coming months and years. Thus, careful consideration
of protective equipment to protect research participants and staff
members, to disinfect tools and labs, and long-term planning for
implementation of remote assessment and/or intervention procedures may prove critical for long-term continuation of studies
should this become a reality. Further still, once rapid COVID-19
testing and antibody assays are proven to be reliable and widely
available, we will have tools that may allow us to alter how we
respond to future waves of COVID-19. If procedures for maximizing
the safety of in-person study activities (modiﬁcation of space for
face to face visits, restructuring of waiting areas to separate participants/patients, stringent PPE procedures, etc.) can be implemented immediately following the current outbreak, these
methods paired with new COVID-19 testing procedures may
redeﬁne how we respond to future COVID-19 pandemic events. For
example, most TMS clinics around the world were shut down for
depression treatment following the initial COVID-19 outbreak,
preventing access to care needed by patients. If careful in our current and future response, different approaches for safely continuing
such activities may be possible. We can consider developing institution speciﬁc standard operating procedures for the labs and
orientation of all staff members to deal with future outbreaks. As
such, we provide a summary of important considerations for
response to COVID-19 as well as a checklist for adapting research
and treatment practices to COVID-19 in Table 3.
Recommendations (checklist) for adapting research and treatment
practices to COVID-19
Here we provide a list of recommendations for adapting
research and treatment practices to COVID-19 pandemic.
1) Conduct a systematic updated risk-beneﬁt analysis of each
protocol to decide for each effort if it should continue and

Name of the
institution

Start date of
restrictions

(Planned) date of
easing the
restrictions

Restrictions

Phase 0

Phase 1

Phase 2

Australia

Monash University
and Epworth
Healthcare

Beginning of April

To be decided,
returning to
campus is allowed
after June 1, 2020

 Interruption of ongoing
preclinical studies
 TMS studies suspended

 Implementation
of
teleworking
 Data collection from remote
studies

 Basic hygiene precautions*

Austria

University of Graz

March 11, 2020

Mid-May

 All ongoing studies and
in-person activities
suspended

 Data
loss
from
ongoing studies
 Interruption of data
collection
 Re-organization
of
tDCS studies for
remote
administration
 Follow-up
of
recruited
participants
 Interruption of data
collection

 PPE
 Sanitization protocols
 Single-subject test sessions

Belgium

 Libre de
Universite
Bruxelles

March 15, 2020

To be decided

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection

Belgium

Ghent University

March 17, 2020

May 4, 2020 (under
strict safety
conditions)

 Interruption of research
activities (preclinical and
clinical)

Brazil

Federal University
of Espírito Santo

March 18, 2020

To be decided

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection
 Data
loss
from
ongoing TMS studies
 Interruption of data
collection

 Implementation
of
teleworking
 Implementation
of
teleconferencing
 Strengthening collaboration
across centers
 Implementation
of
teleworking
 Implementation
of
teleconferencing
 Implementation
of
teleworking
 Implementation
of
teleconferencing
 Implementation
of
teleconferencing

Brazil

University of Sao
Paulo

March 12, 2020

end of July

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection






Canada

University of
Calgary

March 20, 2020

Likely May or June
2020

 Interruption of most
clinical operations;
continuation of urgent
patients and acute care

 Interruption of data
collection
 Early career scientists
losing time and
opportunities

 Virtual clinics
 Pooling data across labs for
new analysis opportunities

Data mining
Computational modelling
Remote patient follow-up
Implementation
of
teleconferencing
 Development
of
a
questionnaire to measure
COVID-19-related anxiety

 To be decided

 Continuation
of
teleconferencing
 Basic hygiene precautions*
 Basic hygiene precautions*
 Checklists for staff and
patients
 Rescheduled
treatment
sessions
 Shift
schedules
for
all
professionals
 Individualized devices and
single-use packages for
stimulation
Immunity passports
 Basic hygiene precautions*
 Checklists for staff and
patients
 Rescheduled
treatment
sessions
 Shift
schedules
for
all
professionals
 Individualized devices and
single-use packages for
stimulation
 Immunity passports
 Priority to young early career
scientists
 Structured screening system
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Table 2
COVID-19 and International Accommodations in Brain Stimulation Research SettingSurvey
data were collected from April 30, 2020 to May 6, 2020. To date, data on 28 institutes have been collected from 17 countries. Phase 0 refers to the challenges that affected research activities with respect to COVID-19. Phase 1 refers
to what activities have been implemented in response to the pandemic. Phase 2 refers to the precautions planned or already implemented during the reopening of NIBS labs.

China

Shanghai Mental
Health Center

Jan 29, 2020

May 2020

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection

 Interruption of data
collection
 Regular meetings for
Journal Clubs were
stopped
 Interruption of data
collection
 Delays in projects
 Potential depletion of
project funding

 Implementation
teleworking
 Implementation
teleconferencing
 Re-analyzing
collected data
 Implementation
teleworking
 Implementation
teleconferencing

of
of
previously
of

 Basic hygiene precautions*
 Controlled
entrance
to
campus

February 1, 2020

Denmark

Copenhagen
University Hospital
Hvidovre

March 13, 2020

To be decided,
treatment-related
research is resumed
after May 4, 2020

 All ongoing studies and
in-person activities
suspended

Denmark

Technical
University of
Denmark

March 12, 2020

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection
 Delays in projects
 Potential depletion of
project funding

 Implementation
teleworking
 Implementation
teleconferencing

of

Max Planck
Institute for Human
Cognitive and Brain
Sciences

March 13, 2020

To be decided,
partial reopening
with some lab
activities and inperson work with
patients after May
4, 2020
April 27, 2020 (with
restrictions)

 All ongoing studies and
in-person activities
suspended

 Implementation
teleworking
 Implementation
teleconferencing

of

University Medical
€ttingen
Center Go

March 20, 2020

 Interruption of data
collection
 Having to close a
study without
meeting the
predeﬁned sample
size
 Interruption of data
collection
 Pause of recently
started studies
 Lower
statistical
power for studies
terminated earlier
 Interruption of data
collection

 Implementation
teleworking
 Implementation
teleconferencing

of
of

 Shift
schedule
for
all
professionals
 Rescheduled
treatment
sessions
 Social distancing rules

 Implementation
teleworking
 Implementation
teleconferencing
 Implementation
teleworking
 Webinars

of

 Basic hygiene precautions*

Germany

Germany

Partial reopening
from May 4-11,
2020

 All ongoing studies and
in-person activities
suspended

Not speciﬁed

 Non-urgency
suspended

 Implementation
of
teleworking
 Implementation
of
teleconferencing
 Daily updates on COVID-19

of

March 23, 2020

February 23, 2020

April 4, 2020

 Interruption
of
all
preclinical experiments
 Interruption of all inperson study activities

 Interruption of data
collection
 Decreased number of
sessions and
incoming projects

Italy

Novella Fronda
Foundation

March 9, 2020

May 18, 2020

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection
 Data
loss
from
ongoing studies

 Implementation
teleworking

of

Italy

IRCCS Santa Lucia
Foundation

March 9, 2020

May 18, 2020

 Interruption of ongoing
research

 Interruption of data
collection

 Implementation
teleworking

of

Iran

 Training for all researchers
 Mitigation plan based on
national and international
standards
 Reopening gradually
 Screening patients
 Rescheduling patients (only
one at a time)
 Continuation
of
teleconferencing and remote
work if possible
 Sanitization protocols
 Social distancing

 PPE
 Testing of patients

of

Kasturba Medical
College, Manipal
Academy of Higher
Education
National Brain
Mapping Lab
(NBML)

India

activity

of
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University of
Science and
Technology of
China

China

May 2020

 All ongoing studies and
in-person activities
suspended

of
of

(continued on next page)
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 Basic hygiene precautions*
 Measuring the temperature
of patients
 Assessment by a doctor at the
reception
 Instructions for patients and
staff
 PPE or transparent face
shields
 Rescheduling patients (only
one at a time)
 Measuring the temperature
of patients
 PPE or transparent face
shields

Country
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Table 2 (continued )
Name of the
institution

Start date of
restrictions

(Planned) date of
easing the
restrictions

Restrictions

Phase 0

Phase 1

Phase 2

 Home-based
protocols are not yet
approved
April 10, 2020
Students are not
allowed to access
the University from
March 9, 2020

Likely May 7, 2020

 All ongoing studies and
lab activities suspended

Portugal

University of
Coimbra

March 9, 2020

Approximately
mid-May 2020

 All
ongoing
suspended

studies

Russia

National Medical
Research Center for
Psychiatry and
Neurology, St.Petersburg
NCM lab, ETH
Zürich

March 26, 2020

Approximately
mid-May 2020

 All
ongoing
suspended

studies

 Interruption of data
collection
 Data
loss
from
ongoing studies

March 16, 2020

June 8, 2020 for low
risk volunteers
Unclear for
vulnerable
populations

 All ongoing studies and
in-person activities
suspended

 Interruption of data
collection
 Data
loss
from
ongoing studies
 Psychological effects
of COVID-19 might
inﬂuence the data

 Implementation
teleworking

Switzerland

Zürich Center of
Neuroeconomics,
University of Zürich

March 16, 2020

May 15, 2020 (or
sooner depending
on authorization)

 All
ongoing
suspended

 Implementation
of
teleworking
 New lab routines to keep staff
motivated
 Analysis of data from nearly
complete studies

United Kingdom

Institute of
Cognitive
Neuroscience,
University College
London

March 9, 2020

To be decided,
maybe January
2021

 Interruption of ongoing
research

United Kingdom

University of
Oxford

March 13, 2020

To be decided

 Interruption of ongoing
research (clinical and
preclinical)

 Interruption of data
collection
 Decreased
testing
capacity due to
safety precautions
 Fewer
healthy
participants
 Lower
statistical
power for studies
terminated earlier
 Contacting patients is
not allowed for
remote research
purposes
 Illness
of
staff
members (COVID-19
was not conﬁrmed
but symptoms were
similar)
 Support for junior lab
members who live
alone
 Interruption of data
collection

studies

of

 PPE Sanitization protocols

 To be decided

 Basic hygiene precautions*
 Remote data collection if
possible
 Scheduling ofﬁce use
 Measuring the temperature
of participants
 Ventilation of rooms
 Switch to a round coil if
possible
 Basic hygiene precautions*
 Remote data collection if
possible
 Scheduling ofﬁce use
 Monitoring the infection of
staff members
 Measuring the temperature
of participants

 Implementation
of
teleworking
 New lab routines to keep staff
motivated
 Collecting follow-up data
remotely
 Participation
to
online
workshops

 PPE
 Home-based tDCS
 Shift schedules for staff
members
 Social distancing measures

 Implementation
teleworking

 To be decided

of
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Nagoya Institute of
Technology

Switzerland

 Financial
burdens
and uncertainties
 Need to complete all
preclinical research
by the end of ﬁscal
year after reopening
 Potential loss of data
on multiple session
studies

 Computational experiments
remotely
 Implementation
of
teleworking
 Communication
with
collaborators
 Conduction
of
online
experiments later
implemented in the lab’s
work
 Implementation
of
teleworking
 Implementation
of
teleworking

Japan

 Rescheduling patients (only
one at a time)
 Measuring the temperature
of patients
 Assessment of symptoms
 Basic hygiene precautions*
 Ventilation of the rooms

University of
Florida

March 13, 2020

TBD, tentatively
June 1, 2020

 All ongoing studies and
in-person activities
suspended

MA, USA

Beth Israel
Deaconess Medical
Center and Baystate
Medical Center

March 20, 2020

May 18, 2020

 All ongoing studies and
in-person activities
suspended

NY, USA

NYU Langone
Health, New York
NY

March 10, 2020

Early June 2020

 Interruption
of
all
outpatient visits outside
of standard care or
justiﬁed risk

MN, USA

Pediatric
Neuromodulation
Laboratory
University of
Minnesota

March 17, 2020

‘Sunrise Plan’
Implementation In
Process, TBD

 All studies considered
‘non-essential
operations’ on
immediate hold, which
placed infant and child
stroke studies on hold

 Data
loss
from
ongoing studies
 Interruption of data
collection and
recently commenced
studies
 Drop-out of subjects
with interrupted
protocol
 Delayed completion
of multisite clinical
trials
 Need to recruit new
subjects when
restarting the studies
 Data
loss
from
ongoing studies
 Interruption of data
collection

of

 Continue tele-research program with home-based
remotely supervised tDCS
 Protocol for sanitation of
equipment, including
shipments (incoming and
outgoing) of equipment to
participants

 Secured IRB approval for two
COVID-19 related studies in
feasibility/reliability of pediatric tele-neuromodulation
and a Family Impact to
Rehabilitation Access OnLine Survey
 Protocol for training, safety
and implementation of teleneuromodulation in the pediatric population

 Questionnaire or checklist to
assess COVID-19 risk
 Testing for COVID-19
 PPE
 Remote or home stimulation
 PPE
 Alternating
remote
and
onsite schedules for staff
members
 Social distancing measures
 Continue tele-research program with home-based
remotely supervised tDCS

 PPE
 Shift schedules for staff/
trainees
 Social distancing measures
with modiﬁcations for child/
family interactions and infant
positioning for
neuromodulation
 Continue tele-research program with home-based
remotely supervised tDCS to
advance from feasibility/reliability to efﬁcacy
 Testing for COVID-19 as per
University protocols
 PPE for staff/trainees and
participants

(continued on next page)
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 Redeployed research
staff to work
remotely
 Continued
all
ongoing treatments
using remote homebased tele-treatment
(Remotely Supervised tDCS)
 Received
IRB
approval for remote
consenting and
continued
enrollment
 Data
loss
from
studies in process
and cancelled
assessment and
intervention sessions
 Loss of participants
with interrupted
protocol, infants will
now likely age out of
the study dependent
upon safety and date
of reimplementation
 Delayed completion
of clinical trials
 Continuous
monitoring of
inpatient pediatric
census for return to
research and new
recruitment
 Research
staff/
trainees established
for secure at-home

 Implementation
teleworking

 Single-use sponges and head
ﬁxture devices for tES
 Basic hygiene precautions*
 Training
for
staff
and
students
 COVID-19
participant
screening (temperature and
symptom questionnaire
 COVID-19 testing for all staff
 PPE for staff and participants
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FL, USA

 Conducting modelling and in
silico studies
 Implementation
of
teleworking
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2)

3)

access and
productivity

tDCS: transcranial direct current stimulation; TMS: transcranial magnetic stimulation; tES: transcranial electrical stimulation; PPE: personal protective equipment.
basic hygiene precautions*: PPE, sanitization, social distancing.

Country

Table 2 (continued )

Name of the
institution

Start date of
restrictions

(Planned) date of
easing the
restrictions

Restrictions

Phase 0

Phase 1

4)

5)

6)

7)

8)

9)

10)

11)

inform remaining steps; this may include contingency plans
to changes in a given circumstance (e.g. if X happens the trial
will need to wind down under these conditions), engaging all
stakeholders in discussion (e.g. staff, program ofﬁce, DSMB,
etc.), and statistical consultation with respect to the power to
make conclusions regarding protocol changes (e.g. change in
dose, trials terminated prematurely) and associated changes
in outcome reporting (e.g. feasibility instead of efﬁcacy).
Transition as many study procedures as possible to electronic
or video format (e.g. consent process, screening visit,
assessment tools, switch to an established home-based
techniques).
Remove non-essential steps in protocols that require inperson interactions.
Establish stringent safety and sanitization procedures for all
required in-person interactions and train staff in execution of
these procedures (with documentation of training completion). Ultimately, staff will have to follow regulatory and
protection procedures adopted by speciﬁc research or clinical
settings (e.g. nursing home setting) will have to follow
COVID-19measures for that setting; or in-person visit at a
patient’s home will require compliance with COVID19protection mandated for home care. Therefore, developing and updating protocol speciﬁc safety procedures requires research staff communication and coordination with
institutional (clinical) leadership for the speciﬁc setting in
which NIBS studies will be carried out.
Implement all institution required safety procedures (e.g.
screening, PPE, COVID-19testing, etc.). Develop studyspeciﬁc considerations for staff who recovered from COVID19.
Consider changes in intervention that do not impact trial
integrity (e.g. number of visits, inclusion/exclusion) or
consider changes that strategically change trial scope (i.e.
still allow for meaningful publishable outcomes; e.g.
changing to a pilot trial).
For in-person protocols, streamline the entire process from
participant preparing to leave their home, to transportation,
to arriving at clinic/lab, to leaving the clinic/lab to maximize
social/physical distancing (including between patients and
between staff) with special attention to neuromodulation
steps; where possible, the clinical trial may provide support
for car service for participants to avoid public transportation.
Add additional telemedicine steps (follow-ups) to adjust for
changes in protocol; Add steps responsive to COVID-19
related concerns. This can include additional data collection
that may impact immediate decisions (vii) or later analysis
such as testing all subject temperature or surveying for
COVID-19 related symptoms. Determine protocol for identiﬁed COVID-19 positive patients, including if they are not
critically ill or without symptoms.
Review explicit protocols/consideration for adverse events
(related or not to the intervention) so that the decision tree
(what to do, who makes the call, what needs to be reported)
is mapped out beforehand (patient or caregiver has X
symptoms leading to Y actions).
Obtain IRB approval for any applicable changes (e.g. all the
above) in protocol including patient consent in regard to any
new anticipated risks.
Take steps to share your plans, lessons, learned, and ongoing
experiences with the broader community. Survey all stakeholders (e.g. building facilities, research personnel) to gauge
comfort with planned activities.

Table 3
Summary of considerations for COVID-19 response.
Initial

During










Continue remote/teleworking activities such as analyzing data, manuscript writing, grant preparation, virtual meetings, adverse event follow-up, etc.
Plan for study procedure changes to maximize participant safety and social/physical distancing (e.g., PPE and other safety procedures, facility and equipment disinfection)
Plan for possible re-integration strategies (tiered, split, etc.) and how the team will adjust to accommodate institutional strategies
Prioritize study activities that will occur in-person once stay-at-home mandates are lifted to account for overburden of study teams due to prior missed visits, upcoming follow-up assessments, and need for new
participants to replace those with interrupted and unrecoverable intervention schedules.
Consider revision of ongoing studies to minimize person-to-person contacts through remote/online/teleassessment for questionnaires, self-report measures and other items not requiring in-person administration
Consider necessary redesign of study space to minimize participant contact time during intervention delivery
Further evaluation of feasibility for movement to remote assessment and intervention administration as a precaution for future COVID-19 related stay-at-home mandates.
Consider procedures for implementation of rapid COVID-19 testing and antibody assays noting and depending on any limitations in current testing and antibody assays regarding sensitivity, speciﬁcity or established
relevance to risk.
Explore e-consenting procedures and e-questionnaires etc.
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 Cessation of non-essential in-person research activities
 Followed by determination of compatibility with continuation through valid remote assessment and/or intervention methods
 Movement of study teams to remote work to adhere with stay-at-home mandates
 Special consideration required for remote access to resources (hardware, software, etc.)
 Potential continuation of patient studies deﬁned as essential care (e.g., depression), institution-speciﬁc determination
 Allow reduced numbers of study team members to remain at work to continue essential study activities (e.g. shift or staggered working patterns)
 Communication with all participants currently enrolled in ongoing studies to provide information regarding how their participation in the study will be impacted by any stay-at-home mandates.
 As applicable, communication to participants around any potential risk of COVID-19 transmission in relation to ongoing participation.
 Provide participants with additional information regarding available local resources (e.g. telemental health services, community assistance programs, etc.)
 Training speciﬁc staff or consider additional personnel resources for coordinating COVID-19 safety procedures

Future





Consult reputable sources (IRB, CDC, FDA, etc.) for guidance on the timeline for study restart.
Devise a mitigation plan to limit exposure to Covid-19 or any other infectious agent for study subject/participant as well as research staff
Immediate implementation of planned procedures and updated safety precautions (i.e. standard operating procedure documents), with appropriate staff training.
If appropriate procedures for participant/patient safety (PPE, facility design, etc.) and other required procedures are implemented following the ﬁrst wave of COVID-19, consider how the implementation of rapid COVID-19
testing and antibody assays may allow for the continuation of appropriate in-person activities that were immediately discontinued in the initial emergency response to the ﬁrst COVID-19 outbreak. This decision will be
institution speciﬁc.
 Consider creating a ﬁnancial plan involving possible sources and a calculation on the costs in case of subsequent outbreaks (e.g. the acquisition of all necessary equipment)
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Regulatory factors
Trial registry (e.g. ClinicalTrials.gov) report updating
All clinical trials registered with a database such as ClinicalTrials.
gov should be appropriately updated to reﬂect the mitigation plan
to limit risk of infection, a revised timeline for enrollment and any
social/physical-distancing related adaptations to the protocol. Participants may be more willing to enroll knowing that precautions
have been made.
Institutional Review Board/ethics review board approval
Some ethics boards may mandate withholding research
recruitment for some period at peak of outbreaks. While pausing a
study does not necessarily require notiﬁcation to the IRB/Ethics
Board, any protocol changes to the process of interaction, intervention or assessment of participants must be reviewed and
approved by the resident ethics board. This includes but is not
limited to modiﬁcations of the method of administration from inperson to online, shifts to at-home neuromodulation procedures,
change in participant payment method, etc. Study sponsors may
have differing timelines for study restart than local institutions and
ethics boards.
Converting to a video/online consent process
Many research groups are now converting their consent and
screening visits to a tele-health/video-visit. The term most
frequently used is “e-consent or e-consenting”. The requirements
for this vary by Institutional Review Board, but all contain the core
features of providing the prospective participant with a copy of the
Consent (e.g. via mail or email), going over the Consent remotely,
and obtaining a signed copy of the Consent (e.g. mail or email)
which the investigator countersigns on the date of receipt. Once the
participant signs the consent, typically with either video observation or through a secure online signature process, this enables the
investigator to proceed with the screening visit, which can be
facilitated using electronic forms (e.g. RedCap, Qualtrics, ClinCapture). Such video/online consents and video/online-based
screening visits lessen the risk of contracting the illness for
everyone, and may provide a more effective means of performing a
Consent visit involving all necessary safety precautions (masks,
disinfection, etc.).
Communication with funding agencies and data safety monitoring
boards
Study suspension and any revisions to procedures within funded studies should be discussed with the funding agency. In addition, for clinical trials with a standing data safety monitoring board
(DSMB), study suspension and restart as well as changes in study
procedures should be forwarded to the DSMB for approval.
Extensions of funding for research
In most places across the world, neuromodulation studies have
been suspended, yet the costs associated with those experiments
(e.g. salaries, animal housing and food costs) have continued. This
placed a ﬁnancial burden on these studies and will also delay the
ﬁnal results of the studies. Thankfully, several funding agencies,
including the US National Institute of Health, Wellcome Trust and
the Medical Research Council UK, and Swiss National Science
Foundation have announced the ability to apply for an Administrative or grant Supplement to cover unforeseen COVID-19-related

costs. They have also streamlined the process for getting approval
for a No Cost Extension. These steps offer signiﬁcant relief to researchers and increase the likelihood that the dedicated resources
already invested in these projects will be fruitful.
Human resources considerations
Supporting our colleagues, particularly Early Career Researchers, is vital in this time of crisis. There are a number of issues
that this period brings; here we will discuss some of the most
pressing. This cannot be an exhaustive list, however, and it is vital
that as a ﬁeld we are sensitive to the additional needs of our colleagues. It is perhaps important to note that we are in no way
encouraging a decrease in the standards required for publication.
Rather, an increase in understanding around the circumstances in
which that work is done is called for.
Firstly, it is vital to recognize the additional anxiety the current
situation will place on Early Career Researchers and PhD students.
For students with only months of funding left with which to
complete their degrees, this is a very stressful time, as it is for those
more senior researchers with grant deadlines. It is to be hoped that
this paper will provide helpful suggestions and contribute to the
discussion for ways to ease the difﬁculties faced at this time,
however, the inevitable anxieties associated with the current situation are real and should be explicitly acknowledged. We must
work to address these and to support our colleagues through this
difﬁcult time.
Research groups around the world will be physically separate,
indeed often spread across time zones if students choose to spend
this unprecedented period at home. This will inevitably lead to
psychological stress, something that has already been seen in China
[13]. Maintaining group cohesion is vital and implementing explicit
support structures is necessary, particularly for those isolating on
their own with families elsewhere [14]. While online tools cannot
replace face-to-face interactions, they are vital substitutes in current times. The vast majority of labs will have moved work meetings online already, but in addition to these it is important to
recognize that for many work is also a social experience and now
more than ever, an essential source of support. Scheduled coffee
breaks, games nights, ﬁlm nights, cocktail hours (with alcoholic or
non-alcoholic drink of choice) and many other social events are all
being implemented successfully across the world to create at least
some of the social interactions so important to both our mental
wellbeing and our lab cohesion. Explicitly matching group members in a buddy-scheme, where each lab member has a partner that
they have to contact even brieﬂy each day, is a way of providing a
light touch method to ﬂag potential mental health issues early.
While we cannot prevent the inevitable increased rates of mental
health problems in our community, making sure that we explicitly
discuss the difﬁculties we all face in this pandemic, and the inevitable mental health repercussions, will hopefully allow those facing
particular problems to speak out and receive the support they need
[15].
It is necessary to act now to ensure that the current pandemic
does not have long-lasting negative consequences on the ﬁeld. NIBS
has historically had a lack of female representation [16], something
that leaders in the ﬁeld have made a concerted effort to address in
recent years [17] with increasing success. However, the current
crisis is likely to exacerbate the gap between women and men, and
between carers and non-carers, in terms of available time and opportunities. The burden of care and responsibilities have fallen
unequally in this crisis - for some this is a virtually unheard of
period of quiet in which they have the time to produce as much, if
not more, work than normal. However, for the ﬁeld as a whole it is
vital to recognize that for others this is a time where demands and
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anxieties have increased, and available time has shrunk considerably. The “room of one’s own in which to write” [18] is for some a
daily reality and for others merely a distant dream. The real effects
of this inequality across academia is already being spoken about
anecdotally by editors, who report decreases in the number of
submissions from women [19] and, possibly, increases in the
number of submissions from men. How those trends continue will
need to be carefully monitored.
While it is extremely difﬁcult to judge what effect other responsibilities may have on our colleague’s productivity, it is timely
to recognize that although individual circumstances vary substantially on average women still carry the majority of the burden of
both caring responsibilities and household tasks even when both
partners work [20] - something that can at the moment only
exacerbate gender imbalances in the ﬁeld. It must therefore, be the
responsibility of all of us, particularly those in more senior positions, to acknowledge this and to challenge the potential prejudices
of others and ourselves when making career-determining decisions, not just at the moment but in the months and years to
come. Suggestions have already been made as to ways to tackle this,
including explicitly treating this period as carers leave in future
applications [21].
In the shorter term, the social/physical distancing measures in
place around the world are not only limiting what we can do in
terms of science, but limiting the opportunities for all of us,
particularly the Early Career Researchers, to network and to meet
potential advisors for the next stage of their careers. Initiatives such
as on-line conferences are likely going to be the mechanism for
sharing our science for at least the next few months and provide an
essential opportunity for our ECRs to discuss their work. However,
what is difﬁcult to reproduce on-line is the informal chat over
coffee with others in the ﬁeld, which can often provide the start to a
conversation that ends with a postdoctoral position or support for
tenure-track applications.
Overcoming these restrictions will be difﬁcult: by deﬁnition it is
challenging to formally engineer informal discussions. We all have
a responsibility to recognize this, and to be responsive to unsolicited emails from researchers elsewhere. This is also a time to
embrace the ability to invite speakers from around the world to
give informal talks at lab meetings and small gatherings without
the costs involved in travel. Not only does this broaden our horizons
at a time when it is all too easy to reduce our interactions, it also has
secondary beneﬁts. Small lab talks provide excellent opportunity to
interact with external researchers in a small group. Inviting senior
researchers to speak can provide a route into discussions for ECRs,
inviting ECRs to speak provides valuable experience for them.
In practical terms, many universities have relaxed the timescales
required for PhD students, something that we must support and
petition for. Many grant bodies around the world have already
announced blanket extensions to current funding - as a ﬁeld it is
our responsibility to make these allowances as equitable as
possible. A number of routes through the current crisis have been
suggested in the rest of this article which will allow us to continue
our research with disruption kept to a minimum. However, in the
inevitable rush back to the lab, for the long-term sake of the ﬁeld
we must not forget to bring everyone with us.

General guidance in reopening labs/clinics
As with all COVID-19 safety procedures, regional and institutional guidances, applied judiciously to speciﬁc protocols considering changing conditions, will determine which procedures
should be implemented and which can be abbreviated. Our recommendations below explain a range of existing procedures in the
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context of NIBS application and should not be considered necessary
or sufﬁcient for every situation.
Social/physical distancing protocols
A critical factor in controlling and reducing the spread of SARSCoV-2 and the associated COVID-19 has been so-called social/
physical distancing, which means preventing physical contact
especially of persons who otherwise would not have social contact.
What is essential to understand here is that the terminology “social/physical distancing” may be somewhat misleading, as what
matters in essence is the physical distancing. The latter in turn has
mainly been recommended because one dominant way by which
SARS-CoV-2 is transmitted is by airborne droplet infection. More
speciﬁcally, aerosols emanating from the upper respiratory
pathway housing the virus in high concentrations are thought to
passively “travel” through the air and remain airborne for some
time. While the exact travel distance and the amount of time that
infectious materials maintain in the air are currently a matter of
debate, most recommendations suggest keeping (at least) 2 m (6 ft)
distance to any other person and assuming that any unknown
person could potentially be infectious [22]. Minimizing duration of
contact is another strategy that may be considered based on study
protocols, current federal and institutional guidances, and current
scientiﬁc consensus on impact of briefer contact times (protocols)
in reducing risk to operators and patients.
Social/Physical distancing parameters as deﬁned by governments and regulatory authorities vary among countries, states and
counties and change over time as a regional Covid-19 situation
develops. The following procedures are therefore region and
institute speciﬁc, and subject to ongoing risk-burden evaluation. As
applicable, social distancing should be maintained in all ofﬁces. The
allowed density of staff in given rooms should be considered along
with the need for and mechanism of minimizing face-to-face
interaction (e.g. by using chat, emails or telephones). As applicable to the speciﬁc time and protocol, it may be prudent to wear
masks and maintain a recommended interpersonal distance. If and
when patients should wear masks for necessary clinical treatments
should be determined. For studies and therapies where wearing
masks hinders the efﬁcacy, transparent face masks could be
considered.
During NIBS procedures, it is often not possible to maintain the
recommended physical distance, at least for some amount of time.
For instance, applying electrodes for tES or adjusting the position of
TMS coils requires direct contact between the person applying NIBS
and the person receiving NIBS. Robotic TMS provides some opportunity for TMS administration with operators further removed
from participants (easily by 2 m/6 feet except for brief localization
to navigation, though the participant can be trained to do this).
However, such devices will not be available to all labs and clinics. In
these instances, protective measures are important to reduce the
inhalation and expiration of aerosols, and the amount of time,
during which the recommended physical distance cannot be
complied with, should be restricted to a minimum possible.
Personal protective equipment (PPE)
PPE can take many forms such as wearing face masks that
should cover both mouth and nose. There are different safety
standards for these masks, and we recommend that medical and
research personnel in constant contact with potentially infected
persons (including participants and patients, but also co-workers)
wear those with the highest safety standards (e.g. N95 masks).
Importantly, the masks should be regularly changed (with maximal
wear time differing as per the speciﬁc type and make of the mask)
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as otherwise they might even be counterproductive due to the
accumulation of viral material at the inner side of the mask. If
appropriate, patients and participants may be provided with single
use or disinfected multiple use masks by the neuromodulation labs.
As appropriate, in addition to masks, medical and research
personnel may consider wearing transparent visors, or protective
eye wear covering the upper parts of the face and especially the
eyes, through which viral material can also easily enter the organism. Visors that cover the whole front of the face extending way
down below the chin may supplement face masks for researchers
and participants. In theory, the appeal of visors without masks is
allowing better verbal communication, compared to face masks,
which limit articulation and comprehensibility of speech sounds
i.e., the “mufﬂing” effect-b but such considerations are secondary to
safety. The appropriateness of visors and other PPE (e.g. goggles,
protective coats) in various social and clinical environments will
ultimately depend on current regional and institutional guidances.
In some regions and institutions, current recommendations are to
use both a surgical mask and visor for direct interactions with
patients.
Moreover, medical and research personnel should wear single
use gloves when touching participants and patients, and the latter
may also want to be provided with such gloves when touching
apparel that will be touched by others, such as input devices,
computer keyboards, desks, etc.
Facilities and sanitization procedures
As with all COVID-19 safety procedures, regional and institutional guidances, applied judiciously to speciﬁc protocols considering changing conditions, will determine which procedures
should be implemented and which can be abbreviated. Our recommendations here thus index possible applicable procedures.
Besides body-worn protective measures, room dividers and
transparent shields can be considered for installation in facilities
that are not already designed for one-on-one visits. These devices
constitute a physical barrier hindering the spread of aerosols
throughout the room from participants and patients to personnel
and will be especially important at patient receptions. Provisions of
hand washing opportunities, or hand sanitizers for patients and
participants at the entrance to research and treatment premises are
also generally recommended, and they should be provided in a way
that they can be regularly and easily used by medical and research
personnel, after each new contact with a new person. Additional
measures to minimize airborne particles being transmitted are
regular ventilation of research and treatment laboratories, regular
disinfection of surfaces, such as doorknobs, apparel, furniture,
research equipment and visors as well as shields, ideally after each
use by a new person, is highly recommended. Within elevators,
covering all buttons with plastic membranes that are changed daily
is advised. Tissue paper or small wooden pieces can be provided to
push the button without skin contact.
Special consideration should be given for employing single-use
equipment when possible. For example, within tES, a variety of
single-use and multi-use electrodes is available. Maximizing the
use of single-use devices that contact the participant/patient serves
to minimize potential translocation of virally active material from
one participant to the other. Where devices must be used across
participants, antibacterial disinfection may not be sufﬁcient. In all
cases, all research equipment should be sanitized/disinfected
before and after use. In this, special consideration as to which type
of disinfectant is used needs to be applied, as the functionality of
some electrodes may be negatively affected when disinfected with
alcohol-based disinfectants. One potential alternative to alcoholbased disinfectants is the use of Hydrogen Peroxide. We

recommend referring to manufacturer information to evaluate
possible disinfection routines. All disposable supplies should be
discarded in appropriate bio-waste repositories. Note that most of
the considerations regarding sanitization protocols should not only
be applied to laboratories and treatment facilities, but also for the
off-site home use mentioned above in this paper.
The following disinfection and sanitization protocols are aiming
to give research facilities some ﬂexibility to re-start NIBS clinical
services and research operations during the current COVID-19
pandemic and possibly similar outbreaks in the future for patients with non-COVID-19 needs or complex chronic disease
management requirements.
C After the NIBS session is over, the environmental surfaces in
the stimulation room should be sanitized using a 1% Hypochlorite solution, with a disposable antiseptic cloth [23].
Also, all the stimulation equipment, including magnetic coil
(for TMS) stimulator, electrode/stimulator cables, EEG cap,
tape measure, electrodes and sponge pockets should be
sanitized. Follow manufacturer speciﬁc guidance on how to
clean the stimulator. Furthermore, it is prudent to check for
any leaked ﬂuids from the participant on the stimulation
chair.
C The stimulator trolley and treatment chair should be wiped
with a permitted cleaning product (normally bacillocid is
allowed, but it is better to check with the manufacturer).
C If an MRI/MEG-compatible stimulator is available for concurrent application of NIBS during the recording of neuroimaging or electrophysiological data, then the gantry and the
RF coil should be sanitized with a permitted cleaning product. The MRI table also should be sanitized with any of the
approved products. The coils need to be disinfected once
again after the scanner room is thoroughly sanitized, then
the next patient or participant may be taken [24]. It is
necessary to ensure that the metal nose piece of surgical
masks, if applicable, is not ferromagnetic [25].

Vulnerable populations
An additional aspect that requires consideration is the inclusion
of individuals that belong to high(er) risks groups, both on the side
of the personnel and the research participants or patients.
Currently, older age, a history of cardiovascular diseases and diseases affecting the respiratory system (e.g. asthma, smoking), but
also diabetes, obesity and cancer or other diseases affecting the
immune system directly or through immuno-depressant treatment
(e.g. multiple sclerosis [MS]) are widely considered as major risk
factors (see e.g. Refs. [26], for a meta-analysis). However, what
constitutes a major risk to develop COVID-19 is still not deﬁnitely
established scarce, and we thus recommend to closely monitor the
accumulating scientiﬁc evidence in this respect (e.g. via [27]). For
now, we recommend that individuals belonging to the groups
mentioned, as well as individuals being in close regular contact
with individuals belonging to such groups, should only enter
studies or be treated under special circumstances and with utmost
care.
A logbook of each lab and treatment room should be maintained, listing personal interactions that took place so that in case of
an infection, all persons in contact with the infected person can be
traced back and informed about a possible infection. In such cases,
we strongly recommend swift reactions, including quarantining of
the potential new carriers, exclusion from work premises, and rapid
testing for SARS-CoV-2.

M. Bikson et al. / Brain Stimulation 13 (2020) 1124e1149

On a critical note, many of these measures are not based on
concrete evidence on their effectiveness. There is still insufﬁcient
knowledge about which of them are necessary and sufﬁcient to
prevent further spread of the virus. However, to the best of our
current knowledge, they can be expressed as strongly recommended. Another critical aspect is whether the measures can be
implemented consistently. In many countries, for instance, masks
but even disinfectants are still not available in the required quantities and using the limited number of protective measures for
protection of healthcare workers treating COVID-19 patients should
be given higher priority than using it for neuromodulation
research.
Personnel, participant and patient screening
Additional precautions are regular (self-)screening by
personnel, patients and participants, for potential infections or
contact with infected persons. This can be achieved by a symptomschecklist, which every person entering the research or treatment
premises has to provide, as well as by temperature measurements
at the entrance to the research facilities. All of the latter, however,
may be of limited validity, as many persons infected by SARS-CoV-2
have been reported to be asymptomatic, and do not develop the
associated disease (and thus will neither show symptoms,
including fever). Many institutions have plans to implement either
rapid COVID-19 testing and/or COVID-19antibody testing of faculty
and staff prior to reentry into the workplace. In addition, some
institutions are considering requiring all study participants to undergo rapid COVID-19 testing prior to in-person study activity.
Availability and implementation of these tests will vary across
institutions.
The scientiﬁc basis for SARS-CoV-2-related immunity and reliability of antibody testing remains under development. Subject to
ongoing scientiﬁc insight and respecting regional and institutional
guidance, screening for antibodies in the blood of staff or participants could be one element supporting the basis for an “immunity
passport” or “risk-free certiﬁcate” that would enable individuals to
return to work or research assuming that they are protected against
re-infection. In this respect it should be noted though that a previous infection and the development of immunity may not protect
against another episode of infection, and development of the disease (see e.g. Ref. [28]). However, whether the immunity passport
policy will apply systematically or not, there is value in speciﬁc
protocols and based on broader COVID-19 situation factors in
applying such tests during recruitment procedures to improve
patient-clinician safety or trial integrity.
Speciﬁc clinical populations
Stroke patients
Stroke survivors can experience a wide range of impairments
and disabilities including motor deﬁcits and the loss of ability to
produce and/or to understand language (aphasia). Among other
treatments, use of neuromodulation techniques has been proposed
to enhance/facilitate stroke-recovery. Past studies have integrated
centrally acting tDCS with peripherally acting intensive motor or
language rehabilitation protocols [29e37]. Before COVID-19, there
were several tDCS aphasia treatment protocols published with
positive outcomes [38] but during the ﬁrst half of March, the
pandemic forced most of the labs involved in NIBS and stroke recovery to suspend clinical and research activities. COVID-19 has
signiﬁcantly increased the risk of social isolation and associated
depression in people with aphasia. Indeed, language and cognitive
problems limit the use of digital media (i.e. cellular and/or social
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network) to maintain social contact. Patients with motor symptoms
have also been penalized as a result of COVID-19 since it might be
more difﬁcult for them to move or get around with limited caregiver and physical or occupational therapy support. Stroke patients
being in an older age category increase the risk of contracting the
virus and potentially having a worse outcome; thus, in order to
contain the exposure, they will probably be forced to stay-at-home
for a longer period than young people augmenting the possibility of
psychological distress and depression. To address these mental
health issues, researchers from the aphasia research lab at the
IRCCS Santa Lucia Foundation in Rome have launched an online
interview in the aphasic population to evaluate whether anxiety
and fear towards COVID-19 contagion would discourage the restart
of rehabilitation. One concern is that patients worried about
COVID-19 may be deprioritizing their neurorehabilitation needs
and may develop an attitude of resistance towards clinical research,
deemed non-essential.
Assuming that regulatory agencies and medical centers will
hopefully lift the research and clinical treatment suspensions in the
coming months when appropriate mitigations plans are in place, it
is important to consider that tDCS protocols for motor and/or
aphasia rehabilitation will be hampered by the difﬁculty in maintaining an adequate safety distance during electrodes application
and even more importantly by the mandatory use of masks. Indeed,
for language and cognitive interventions, it is extremely important
that both the therapist and the patient understand each other,
being able to see their mouth’s movements (i.e. ‘lip-reading’ is
known to facilitate communication). Transparent face shields
without masks might be a good alternative option here. However,
these will not resolve the question of electrode application while
keeping a safety distance. Another possibility is to develop remote,
but supervised and controlled interventions at the patient’s home
using home-based tDCS devices. As appealing as this sounds,
considering that most patients have cognitive and physical limitations in applying the ‘kit’ and that NIBS approaches require a peripheral intervention (e.g. traditional speech therapy or physicaloccupational therapies), it will be challenging to provide these
combined approaches in a patient home. For stroke patients, there
might be also an option to develop remote intervention in an
outpatient clinical setting ensuring that there is enough separation
and physical distance between the patient and the investigators.
There is no doubt that requests will be made to regulatory agencies
to allow for clinical research in stroke recovery to be conducted in a
remote way or at the patient’s home by integrating tDCS with other
telerehabilitation techniques and digital interventions e.g. computer delivered rehabilitation. In this way, we may resolve the issue
related to language distortion due to wearing a cover that, masking
not only verbal communication but also facial expressions, would
anyway hinder communication exchanges. Moreover, since some
tDCS language protocols have already been validated, we might
think of offering caps to the patient’s family with the position of the
electrodes already ﬁxed to facilitate and standardized application.
However, we must be mindful that by doing so we may be limiting
the breath of patients we can study and the generalisability of our
ﬁndings e.g. only those who have prior experience using digital
technologies, with limited cognitive difﬁculties, who have family
members that can monitor and assist putting on the ‘home-kits
would beneﬁt from those treatments. We also have to consider the
safety of the remote tDCS protocols. Patients might be at a risk of
seizures after stroke and fatigue is an important factor which might
interfere. So timing and careful monitoring of the remote interventions are additional variables to take into account. Considering past remote neuromodulation studies and current COVID-19related problems, tDCS protocols either at home or in a remote
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location at a medical center (separating the patient from the
clinician) may be an opportunity as well as a challenge in the future.
Pediatric research
For over the last decade, neuromodulation has been safely integrated in pediatrics with myriad diagnoses and disorders and
promising outcomes [39,40]. Protocols have integrated TMS, repetitive transcranial magnetic stimulation (rTMS), tDCS and thetaburst in varying age ranges from infancy through young adulthood.
Although commenced in adult populations, pediatric teleneuromodulation protocols have not yet been established. In
response to COVID-19, the Pediatric Neuromodulation Laboratory
in the Medical School at the University of Minnesota, in conjunction
with physicians from Gillette Children’s Specialty Healthcare, and
Mayo-Rochester, have developed an online survey investigating the
impact of COVID-19 and the stay-at-home mandate on family/child
access to rehabilitation care for children with cerebral palsy. Pediatric Investigators in our Department of Psychiatry are also integrating our protocol to run a parallel survey, for families of children
with related psychiatric diagnoses. We are now commencing a
novel pediatric telehealth NIBS study investigating tDCS in the
home setting via remote/telehealth speciﬁcally for children with
perinatal stroke and resultant cerebral palsy. This study is informed
by our previous adult stroke neuromodulation telehealth studies,
and previous established guidelines. The ﬁrst phase of this study
will investigate the feasibility and reliability of parents/caregivers
in operating the device and positioning the electrodes. Phases
thereafter will establish child tolerance and safety, along with
administration and assessment of stimulation in conjunction with
rehabilitation interventions.
Patients with chronic neurological conditions
Neuromodulation is an appealing option for symptom management and rehabilitation for those living with chronic neurological conditions such as MS, Parkinson’s disease (PD) and other
disorders with cognitive or movement dysfunctions, with many
positive signals from the literature and large controlled trials underway. Speciﬁc considerations with these patients include potential cognitive impairments, which may reduce the ability to
understand and complete the required study procedures, as well as
sufﬁcient motor functioning to operate any study equipment from a
remote (home) location. However, in our work to date, we have
found that the majority of those living with MS, ages 18e80 years
and with varying disability levels including wheelchair dependency
and impaired upper limb motor functions, can complete our
remotely supervised protocol with guidance from a tDCS technician. . It is important to include these patients with more advanced
disease for full representation of the disease spectrum because they
often have fewer treatment and rehabilitative options. Continuity
of care for patients in research or clinical protocols is important,
and ongoing communications serve as a connection to the clinic for
those patients with stable disease who otherwise would not be in
contact with their treatment teams during the current time period.

coronavirus spread with congregation of individuals in a limited
space. Alcohol and marijuana sales have also increased as, in many
areas of the world, businesses that dispense/sell these products
have been some of the few businesses to remain open as they are
often deemed essential services. This suggests a burgeoning wave
of drug and alcohol related problems will emerge in society, and
highlights the need to return to delivery of clinical treatment
research in this area. That said, a recent summary by the National
Institute of Drug Abuse highlighted original research demonstrating that chronic smokers and opiate users are likely at higher
risk for COVID-19 related morbidity associated with respiratory
disease [41]. Data from the Chinese Center for Disease Control and
Prevention have suggested that COVID-19 has an increased fatality
in patients with chronic conditions, like respiratory and cardiovascular diseases [42]. An international group of experts on
addiction medicine, infectious diseases, and disaster psychiatry has
recently explored the possible raised concerns and nicely provided
recommendations to a comprehensive healthcare response to
COVID-19 in SUD [2]. To deal with the consequences of the COVID19 on addictions, efforts will require joining partnerships and
possibly unprecedented use of technology in which neuromodulation by NIBS would nicely ﬁt, especially thinking in distance
treatment with an online monitoring system.
Older adults
It has become clear that older adults have the highest rates of
morbidity and mortality associated with COVID-19. Consequently,
older adults represent a vulnerable population and careful
consideration should be made when bringing them into a research
or clinical environment wherein they may be exposed to others
that are infectious. Special consideration should be given in regard
to lab/clinic activities with older adults that have comorbidities that
further increase risk for poor COVID-19 outcomes, such as chronic
obstructive pulmonary disease. While standard PPE, sanitization
and minimization of person-to-person contact should be adhered
to in all participants, it may be necessary to discontinue ongoing inperson research activities for those at the highest risk for infection
and poor outcomes. In-home neuromodulation or treatment options in the daily care units for older people may be a particularly
good option for these individuals. Regardless of comorbidities, labs/
clinics working with older adults should adhere to the highest
standard of safety for minimizing COVID-19 transmission when
continuing in-person research activities.
Vulnerable sub-populations of older adults also include those
with multiple chronic illness and low performance status, such as
those receiving supportive services within the retirement communities (NORC) or community-based patients receiving specialistlevel palliative care. At-home tES paired with telehealth solutions
has been shown feasible in these vulnerable sub-populations. With
proper COVID-19 precautions, screening and PPE protection, noninvasive neuromodulation may provide an option for symptom
management in home settings.
Examples of best practices in brain stimulation labs/clinics
across the world

Addiction
Example 1, NYU remotely supervised or RS-tDCS
The secondary effects of the COVID-19 pandemic (e.g. periods of
lockdowns, closures of routine clinical services and forced selfisolation deriving) have uniquely challenged the health and welfare of people vulnerable to drug and alcohol addiction as well as
those with behavioral addictions (gambling, gaming, compulsive
eating, Internet and new technologies). Inpatient or residential
treatments have been interrupted since the substantial risk of

In the Department of Neurology at NYU Langone Health in
midtown Manhattan, a protocol for remotely supervised tDCS (RStDCS) [43e45] has been systematically developed and validated
over the past ﬁve years with the goal of increasing access to
treatments for larger sample sizes and to extend the number of
treatment sessions. To date, using this protocol, >5100 remotely
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supervised at-home sessions have been delivered to patients with
MS [46,47] and other neurological conditions such as PD [48] and
cerebellar ataxia [49] and following ECT [50], targeting behavioral
outcomes such as cognitive and motor functions and fatigue. While
reducing patient time and costs was the original goal of the RS-tDCS
protocol [51], the COVID-19 clinical research pause demonstrated
the broad utility of remotely supervised at-home treatment for
clinical trials. To date, there are two ongoing RCTs in MS participants, one pairing tDCS with cognitive training for 30 daily sessions
over 6 weeks (National MS Society), and the other pairing tDCS
with upper extremity motor exercises (US DoD) for 20 daily
sessions.
The research team prepared lab computers in advance of the
research pause to administer the HIPPA compliant video visits offsite. Research participants were able to continue their daily treatment sessions without interruptions. We then obtained IRB
approval to obtain informed consent for these trials remotely and
have continued to enroll new participants. We have coordinated
shipping of study equipment in “kits” to our participants that includes a preprogrammed tDCS device, headset, single-use sponge
electrodes, a preconﬁgured laptop computer for the video visits and
survey administration for outcomes. In the motor training trial,
equipment for the daily exercises and assessment measures is also
included. Study kit preparation and shipping (incoming and outgoing) follow a checklist protocol for enforcement in the policy for
cleaning and disinfecting of study materials and all equipment is
marked for visual conﬁrmation of sanitization. A third ongoing
study (National Institutes of Health, NIH) that required baseline and
treatment end neuroimaging visits was able to continue the
treatments for the current participants but with enrollment on hold
until research neuroimaging visits are resumed.
Due to the high demand for access to tDCS from patients with
MS (e.g. those who have had positive beneﬁt in a clinical trial) as
well as those with other chronic neurological conditions, we
received institutional approval for a clinical tDCS service in
December of 2019 as innovative care. This service was launched
through the NYU Langone Virtual Health platform to provide
telemedicine video visits as using our RS-tDCS procedures adapted
for clinical use. Patients are loaned the tDCS device and headset,
with a baseline clearance evaluation and then an intake visit with
agreement forms and device orientation. The virtual visits operate
directly through Epic [52] and is now system-wide throughout the
NYU Langone Health system for implementation of telemedicine.
Patients in the service currently include those with cognitive or
motor symptoms of MS, mild cognitive impairment, and ataxia
[49]. We also have provided the clinical treatment to patients with
traumatic brain injury, post-stroke aphasia, and depression and
cognitive impairment following ECT [50]. There has been no
alteration of this clinical service during COVID-19 and we are able
to see new patients through the outpatient telemedicine platform.
Example 2, University of Minnesota, pediatric transcranial direct
current stimulation
Similar to adults, tDCS has been found to be well tolerated by
children and has promising clinical effects [53]. The challenge of
pediatric in-home telemedicine methods includes safety and
parental compliance [54]. Considering that neuromodulation performed remotely or in the home setting in children incorporates a
vulnerable population and also involves parents/legal guardians,
assessments of safety, reliability and adherence are expanded
beyond the construct of adult studies, and the investigator’s role in
education and remote oversight pivotal.
For over a decade, our Pediatric Neuromodulation Laboratory
has pioneered protocols incorporating neurorehabilitation and
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neuromodulation. The potentially devastating impact on access to
rehabilitation therapies due to the COVID-19 stay-at-home
mandate on families and children with disabilities has yet to be
fully realized. Telerehabilitation, as an alternative means to access
rehabilitation intervention, has been successfully and feasibly
performed in diverse populations of children with disabilities and
by diverse telerehabilitation strategies [54]. Considering the
construct, telerehabilitation in children has been reported to
initially involve face-to-face discussion and education for both the
parents and the child [55]. Additionally, speciﬁc considerations are
indicated for pediatric populations, and integration of parents. In a
pediatric telerehabilitation study aiming to increase treatment
opportunities in cognitive training for children, Corti et al. integrated assessments of the feasibility of interventions and the study
design in the home setting [55]. Key aspects of these assessments
included ‘accessibility, training compliance, technical smoothness
and training motivation’, along with assessments of recruitment,
enrollment and retention. The authors found integration of the
assessments to establish the study well-suited and remarkably high
adherence to the protocol. Inherently, integrating tDCS with telerehabilitation would raise unique considerations, at the forefrontsafety and reliability-with tDCS applications. To date there are no
current publications surrounding pediatric tele-neuromodulation.
Therefore, to adapt our current clinical research neuromodulation
study to a tele-neuromodulation model with supervision for children who are diagnosed with stroke at or around the time of birth,
we are currently integrating guidelines established by Charvet
et al., [47,56] and further work in adult stroke by Van de Winckel
et al. [57].
Our past studies have integrated rTMS and tDCS with intensive
rehabilitation in the pediatric population with perinatal stroke and
resultant cerebral palsy. Now with our latest study, ‘Single -Session
tDCS in Cerebral Palsy’ [58], we are investigating the neurophysiology and behavioral outcomes surrounding tDCS in children with
varying forms of circuitry. We had safely and feasibly completed
sessions in 19 children with stroke by the time COVID-19 put our
study on hold. However, from the commencement of this study,
this study garnered local, national and international interest from
families of children with stroke, many traveling great distances and
incurring staggering related costs of travel to participate. The
COVID-19 challenge has now encouraged us to consider how to
potentially integrate tele-neuromodulation for children at home
and could allow a broader catchment area of families previously
unable to travel and enroll. Integrating accessibility and compliance
in these unique teams of parents/children with cerebral palsy, our
remote training and education laboratory ‘tDCS supervisors’ will
incorporate training the ‘lay assistant’ (parent) as to tDCS delivery,
and the ‘tDCS user’ (child). For ease of tDCS electrode placement,
integration of a pre-marked skull cap with 10e20 electroencephalogram system electrode coordinates, indicating the C3 C4 locations to approximate the primary motor cortex will facilitate
anode/cathode positioning based on the indicated montage. Assessments of reliability of set-up, and electrode placement, and
prior to commencing the stimulation sessions and monitoring
tolerance and impedance will be paramount, along with establishing a consistent and reliable method of remote communication
(e.g. Zoom) during the set-up, stimulation session, and pre/post
assessment trials.
Integrating a COVID-19 response to continue neuromodulation
in the pediatric population with perinatal stroke and resultant cerebral palsy, as well as lack of access recruitment feedback garnered
from our previous work with families nationally and internationally, this remote investigation will inform future larger externallyfunded studies to remotely integrate children with mobility,
ﬁnancial, and access challenges (e.g. rural communities).
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Example 3 NIBS at the university of Magdeburg, Germany
While most of the tDCS-tACS clinical trials were stopped in the
middle of March 2020 in the university of Magdeburg, there is only
one trial running with NeuroConn Mobile devices. The aim of this
phase II study is to collect information about the efﬁcacy of 10 Hz
tACS in the treatment of glaucoma [59], using a domiciliary tACS.
The number of possible stimulation sessions is ﬁxed (34 during 14
weeks) which cannot be changed remotely eand at this stage will
not be changed due to safety reasons. To the best of our knowledge,
this is the longest stimulation duration that was ever applied in this
patient group. Furthermore, none of the stimulation parameters
can be changed during treatment, only by shipping a new stimulation module to the patients. Patients are required to document
adverse events and side effects in a diary and the stimulation
module is saving the parameters of each session, which can be
downloaded in the study center. Unfortunately, several patients
were not able to visit the center at the end of the stimulation session, therefore the objective measurements (e.g. perimetry) are still
missing. The state of the patients is followed by regular phone calls,
two of them indicated to terminate the participation in the trial,
due to high levels of personal stress.

progress in medical science. This example also further highlights
the critical importance of advancing remotely supervised methods
of neuromodulation administration. In ACT, participants complete
cognitive training at home for a large portion of the trial. Were this
initially paired with remote tDCS, the overall impact on ACT would
be signiﬁcantly reduced. However, lack of availability of primary
outcome measures for remote online or tele-administration would
have still led the ACT trial to pause activities. Thus, it is also
important to note that there is a strong need for overarching work
attempting to facilitate remote assessment activities for clinical
trials.
NIBS new opportunities
This section focuses on not simply accommodating the
pandemic situation but using this period to update or enhance
existing NIBS practices using techniques that have already been
validated. We speciﬁcally consider telemedicine approaches using
tDCS (9.1), accelerating in-clinic TMS procedures (9.2), and introducing new NIBS protocols to address existing and emerging
COVID-19 morbidities (9.3).
Tele-neuromodulation (in home)

Example 4, Example from a multisite deﬁnitive phase III tDCS trial at
university of Florida and university of Arizona - augmenting
cognitive training in older adults: the ACT trial
The ACT trial is a multisite deﬁnitive Phase III clinical trial that
investigates the beneﬁts of pairing tDCS with cognitive training in
older adults to remediate age-related cognitive decline and
potentially prevent onset of mild cognitive impairment and dementia [60]. ACT involves a 3-month cognitive training intervention paired with 20 in lab/clinic sessions of either active or sham
tDCS. Participants undergo cognitive training and tDCS 5 days/week
for the ﬁrst two weeks, then complete cognitive training at home
on a study supplied laptop 4 days per week with 1 day per week in
lab/clinic for stimulation. At present, the ACT trial has randomized
307 of 360 older adults targeted for randomization in the trial. As
this trial works with a population at high risk for poor COVID-19
outcomes, in-person study activities were stopped on March 13,
2020. At this time, 22 participants were actively in the intervention
phase of the trial. As ACT is a deﬁnitive Phase III trial near its
completion, a late phase change to at-home tDCS procedures would
signiﬁcantly undermine trial integrity for evaluation of deﬁnitive
beneﬁts from tDCS paired with cognitive training, as only a small
subset of participants would receive the alternative intervention
approach. Even were the current COVID-19 outbreak to occur
earlier in the trial, a signiﬁcant change in intervention procedures
would likely not be feasible for a Phase III trial. In addition, the
primary outcome measure in the ACT trial is currently not available
through telemedicine, further preventing continuation of trial activities through a fully remote process. In ACT, 22 participants
whose interventions were interrupted will need to be replaced. In
addition, approximately 40 participants will miss the timing of
their ﬁnal 1 year follow-up assessment and MRI visits as of the
current date. Careful consideration with the trials data safety
monitoring board and funding agency program ofﬁce will need to
be given regarding whether these 40 participants will need to be
replaced in the trial as well. Pre-COVID-19, ACT was within 14
months of completion. With the loss of 22 participants, the study
will likely not be completed for 24e26 months. Should the 40
participants missing their 1 year time point need to be replaced,
trial completion could be delayed to 36 months or more. While the
extent of delay is still to be determined, this serves as a poignant
example of how COVID-19 is directly impacting the speed of

Considering past remote neuromodulation studies and current
COVID-19 related challenges, ‘Tele-neuromodulation’ holds one of
the greatest opportunities for innovation and growth in the NIBS
ﬁeld right now [61]. Moreover, it is generally the case that the
administration of remote neuromodulation would allow those with
limited accessibility (e.g. mobility issues, geographic location,
ﬁnancial barriers, limited access to communication technologies) to
interventions not previously realized. Rapidly expanding investigations of tDCS in the home setting in adult populations have
been well-tolerated and shown high compliance, and low drop-out
rates in diagnoses such as depression [62], stroke [57], MS
[44,46,47] PD [48], and amyotrophic lateral sclerosis [63], as well as
in seriously ill multi-symptomatic palliative-care patients.
Considering the acute challenges in neuromodulation access for all,
an additional consideration is the expanding ﬁeld of pediatric
telemedicine, with implications for safe and feasible neuromodulation applications in the home setting [54,64,65].
As outlined in case examples (Sections 8.1, 8.2), for those centers
already engaged in remote supervised tDCS, strategic and incremental protocols changes allow continuation (and even expansion)
of protocols. For those centers exploring transition of in-center
tDCS to remotely supervised tDCS, there are well-established
principles under the Remote Supervised rubric that allow homebased tDCS with compromising reproducibility [46] and detailed
supporting documentation [45,56,65,66].
For those protocols providing NIBS treatments that inherently
require in-center application, notably TMS and ECT, and where
COVID-19 related streamlining of in-center protocols is not practical (for speciﬁc patients), transition to home-based tDCS may be
considered as a valid alternative option. There is evidence that tDCS
can extend the beneﬁt of TMS or ECT treatments [50,67]. When ECT
and TMS services are not available the operant decision is not the
comparative efﬁcacy of various NIBS techniques [68] but the risk/
beneﬁt ratio of trialing tDCS. The risk of tDCS is considered nonsigniﬁcant and safe, including across clinical populations [69e71]
- indeed tDCS is broadly applied to healthy subjects (e.g. college
students [72]). Speciﬁcally for major depressive disorder, controlled
trials [73e75], meta-analysis [68,76,77] and expert consensus [78]
suggest tDCS is comparably effective with signiﬁcantly less adverse
events than drug therapy. Consideration for deploying remote-tDCS
treatment should be based on the latest clinical trial data [56].
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In-clinic brain stimulation
While the portability and cost of tES devices lend themselves to
a relatively easy shift toward in-home usage and training, most TMS
studies are currently tied to a ﬁxed clinical or laboratory location,
which is often in a hospital environment. This is a challenge for
researchers that are weighing the cost-beneﬁt ratio of restarting
their therapeutic intervention trials in an environment wherein
participants and staff members may be exposed to the COVID-19
virus. The balance is likely different for mechanistic TMS studies
designed to characterize a disease or biology itself, without any
anticipated therapeutic effect.
That said, there are several sites conducting therapeutic TMS
clinical trials across the globe that have been allowed to remain
open through the COVID-19 epidemic. Even more are resuming
operations as universities, hospital systems, and countries at large
begin to reopen clinical research operations (Section 2). In fact,
while the majority of TMS research trials were put on pause during
the COVID-19 period, clinical delivery of TMS continued in many
U.S. states and a variety of countries for individuals with treatment’
refractory major depression, often with modiﬁed clinical workﬂows
to ensure safety related to COVID-19. Below we will outline topics
that are common to many clinical services and trials that remained
open (or are reopening) as well as some new areas for innovation
and risk-reduction when performing TMS in the COVID-19 era.
Converting consent, screening, and follow-up visits to electronic,
voice, or video format
A common theme echoed in this manuscript is to shift any nonessential in-person visit to electronic/video format. For many
research studies there is a Consent Visit, Screening Visit, and
Follow-Up visits. One of the beneﬁts of the COVID-19 crisis has been
a widespread familiarity and increasing comfort with video
conferencing software (e.g. Zoom, Webex, VSee). It is important to
ensure the security of the videoconferencing platform when connecting with patients or study participants, however, with respect
to institutional requirements for HIPAA compliant communications. Given that TMS studies often require at least one in-person
intervention visit, transforming our protocols to embrace video
techniques for all other visits would improve the risk-beneﬁt ratio
for the staff and the participants. Additionally, research groups may
want to consider adding “COVID-19-related illness” as an exclusionary criterion or as part of the risks for participating in a research
study which relies on multiple in-person visits (should the institution deem this necessary).
Utility of theta burst stimulation
Fixed frequency rTMS (e.g. 10 Hz) is the oldest and most
established stimulation protocol and has been FDA-approved for
use in treatment resistant major depressive disorder for many
years. In recent years however, bursting frequency protocols (e.g.
theta burst stimulation (TBS)) have emerged as highly potent and
temporally efﬁcient forms of brain stimulation; that is, 600 pulses
of intermittent TBS (iTBS) delivered over 45 s result in an elevation
in cortical excitability comparable to 2000 pulses of 10 Hz TMS
delivered over 15 min [79]. The effects of a single session last
approximately 30 min, but repeated sessions have similar durability and efﬁcacy as 10Hz rTMS [80] 34 and were ﬁrst described in
the motor cortex. Several recent, clinical trials applying TBS to the
dorsolateral prefrontal cortex have demonstrated treatment outcomes with iTBS are comparable to treatment outcomes with
traditional 10 Hz rTMS in major depressive disorder. Furthermore,
these protocols have similar side-effects, safety, and tolerability
proﬁles. The advantages of elevated potency and efﬁciency are
coupled with a rigorous biologic foundation as theta is an
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endogenous neural rhythm associated with learning and memory.
By using TBS, the number of patients treated per day with current
rTMS devices can be increased several times without compromising clinical effectiveness or safety. In this COVID-19 era, one way
to minimize the length of the time that a participant or patient has
to be present in the room with a staff member would certainly be
for investigators to consider using bursting frequency rTMS protocols which appear to be more efﬁcient pulse-to-pulse. The
shorter duration of the stimulation session also provides more
ﬂexibility when considering changes in workﬂow and schedules to
ensure that patients do not overlap and thorough infection control
measures are applied after every session.
That said, there has been some concern that the response to
theta burst stimulation is highly variable [80,81]. Although there
have been very few sham-controlled comparisons of ﬁxed frequency versus theta burst frequency TMS, the largest study to
directly compare these protocols (which was not sham controlled),
did not ﬁnd a difference in the variability or the durability of
response to 20 sessions of iTBS compared to conventional 10 Hz
TMS in patients with depression [80]. While the relative efﬁcacy
and durability of these protocols is an empirical question that remains unanswered, in the COVID-19 era it seems that greater
investigation into the factors that increase theta burst efﬁcacy are
warranted.

Accelerated TMS delivery
The development of novel, accelerated TMS dosing strategies is
another opportunity for clinical researchers. Previous studies have
demonstrated that delivering multiple TMS sessions per day has
similar efﬁcacy to a single TMS session per day when the total
number of TMS administrations is equal [82e84]. Given that the
total number of TMS sessions appears to be a critical factor in
behavioral change, these concentrated dosing protocols would be
attractive to both patients and providers. While these protocols are
being explored in research laboratories however, there is still a gap
in our knowledge regarding the parameters that optimally balance
efﬁciency with long-term efﬁcacy. In one of the most concentrated
TMS protocols to date Williams and colleagues (2018) recently
published a study of 6 individuals with highly refractory depression
(5 days, 10 sessions/day, 1800 pulses of iTBS/session, 50 min intersession interval) which demonstrated that this rapid dosing
schedule was feasible and was effective as a rapid antidepressant
[85,86]. Galletly and colleagues (2010), for example, elegantly
demonstrated that TMS delivered 3 times/week achieved overall
similar outcomes to 5 times/week as long as the overall number of
administrations was the same (18-20 administrations) [87]. While
most accelerated TMS studies are being done in Major Depressive
Disorder, they are also being used in many currently recruiting drug
and alcohol treatment research trials [88e93]. These protocols
reﬂect dosing schedules that are likely more tenable for patients
who likely have job and family responsibilities (often 3 days per
week versus the standard 5 days per week). They are being used by
researchers around the world. By decreasing the number of times a
participant or patient needs to come to the laboratory/clinic,
accelerated TMS schedules will also minimize the number of days
that individual spends out of the house, the number of times they
use public transportation, and the number of other personencounters they have over the course of their treatment (as 30
sessions of TMS could be given in as little as 3 or 6 days as has been
tried at various institutions in the United States). On the other hand,
although it reduces the total time of TMS treatment, patients need
to stay longer in the TMS environment, from one or 2 h mounting
up to the entire day.
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Other technologies, such as portable TMS
A few other techniques and opportunities for innovative TMS
protocol adaptations include greater reliance on neuronavigation
for reliable and fast TMS coil positioning (as described in previous
sections of this manuscript) and the delivery of TMS in off-site
community clinics wherein the participant may have less exposure to potential COVID-19 carriers in the hospital environment.
Perhaps the most provocative (but still chimerical) opportunity is
for increased investment and innovation in a portable means for
TMS delivery. There are several patents currently for portable TMS
devices (e.g. for the treatment of migraine attacks Starling et al.
[94]) and several papers have recently been published describing
personalized TMS helmet designs which stabilize the coil [95] and
wearable TMS coil designs [96]. Currently, however, there are no
devices being made for commercial use. The ability to distill the
power of electromagnetic induction as a brain stimulation tool into
a briefcase-sized device has the potential to revolutionize noninvasive neuromodulation as a ﬁeld. To see this materialize from
a fantasy to a reality on the tails of the COVID-19 crisis could, in fact,
be one of the biggest achievements the neuromodulation ﬁeld may
gain from this experience. It will, however, take talent, time, and
investment to make this happen. One should also balance the safety
balance of reducing exposure to the coronavirus with the exposure
to the yet unclear risks of patient self-application of home-based
TMS.
Consideration of tDCS as alternative or adjunctive treatment
As discussed above (Section 9.1). tDCS can be deployed at home
with no or minimal required in-person interactions. On a situation
based, providing tDCS as an alternative to TMS or optimized the
beneﬁts of TMS (e.g. tDCS for maintenance of TMS therapy) can be
considered [97,98].
In conclusion many of the TMS treatment trials that were
temporarily halted in March 2020 around the world have begun to
put strategies in place to return to enrollment and execution. These
decisions should be made with sensitivity to many factors including
the potential risk of COVID-19 exposure to the participants and staff
for in-person visits and the potential beneﬁt to participants & patients of the intervention. Those trials involved structural or functional imaging remains restricted based on the opening of imaging
facilities. Similarly, any TMS trials involving parallel in-person
protocols (e.g. rehabilitation) are considered in totality. While
there will be many factors that inﬂuence this decision for each TMS
study, there are some common themes that will minimize risk
(electronic visits when possible, accelerated treatment courses,
shorter pulse sequences like theta burst, use of technological
methods such as neuronavigation and scalp modeling to improve
rigor and decrease contact) that not only improve the risk beneﬁt
ratio but will likely lead to a reimagination of the future of TMS
delivery-perhaps even launching a new industry that merges the
portability and affordability of tDCS devices with the beneﬁts of
electromagnetic induction as a mechanism of inciting brain change.
New clinical opportunities (indications) with NIBS in the era of
COVID-19
In response to the COVID-19 outbreak, initial psychological and
emotional reactions such as elevated levels of anxiety, fear, stress or
anger and behavioral responses like social/physical-distancing,
stockpiling goods, PPE and disinfectants have been predicted
based on previous experiences [99], and then reported during the
COVID-19 outbreak [100e103]. However, precipitated psychological responses might progress into severe mental concerns which
can easily outlast the pandemic. Sleep disturbances, somatization,
stress-related illnesses, post-traumatic stress disorder (PTSD),

anxiety disorders, depressive disorders and health risk behaviors
such as social isolation, substance abuse or suicide attempts might
also surge [2,15,102]. Accordingly, depressive and post-traumatic
symptoms have been constantly reported and found to persist
even 2.5 years after epidemics [105]. Evidence that similar symptoms are present among health care professionals and the general
population during the COVID-19 outbreak is already emerging from
China, the epicenter of the outbreak [103,106e108], and from
Europe as well [109].
The consequences of COVID-19 might be more immense in
terms of the number of affected and maybe in terms of symptom
severity than previous outbreaks, not to mention its economic and
political impact and their effects on an individual level. Apart from
new cases with mental health issues, those already facing mental
health problems or belong to a vulnerable population might
experience their symptoms worsening [110,111]. Increased risk of
COVID-19 infection or potentially deteriorating mental health
during the outbreak has been articulated concerning patients with
cancer [112], dementia [113], PD [114], chronic pain [115], MS [116]
and drug users [2].
In light of the potential surge of demand for mental health care,
effective therapeutic options are critical. NIBS is a promising and
versatile tool to consider. The administration of magnetic ﬁelds (i.e.
TMS) or weak electrical currents (i.e. tES) induces long-term
neuronal effects through modulating neuroplasticity [117]. One of
the ﬁrst and most successful areas of NIBS application is the use of
HF-TMS over the left dorsolateral prefrontal cortex to alleviate
depressive symptoms that now has a level A evidence (i.e. deﬁnite
efﬁcacy) [4]. Interestingly, promising results are emerging
regarding the beneﬁcial effects of NIBS on several clinical populations suggesting transdiagnostic opportunities. Level B (probable efﬁcacy) recommendation has been proposed for the use of
TMS in ﬁbromyalgia, PD, MS, PTSD and stroke [5]. Evidence is less
conclusive on tES; however, level B evidence supports the utility of
tDCS in depression, chronic pain and ﬁbromyalgia [6]. Moreover,
prosperous results suggest the potential efﬁcacy of NIBS in several
other disorders e.g. in anxiety disorders [118], dementia [119],
obsessive-compulsive disorder [120,121] and pediatric attentiondeﬁcit hyperactivity disorder [122].
In an outbreak situation, adaptation skills and ﬂexibility are
essential to adjust behavior to the new regulations; thus, to mitigate the spread of the virus. Cognitive control is impaired in several
conditions [114,123]; however, NIBS has successfully ameliorated
cognitive impairment in different patient groups [123e125].
Another important skill, emotion regulation has improved in patients with anxiety disorders with the effects being sustained for 3
months after TMS [126]. Depressive symptoms, anxiety and PTSD
emerging or being accelerated by the COVID-19 pandemic [102]
might also be successfully mitigated with NIBS based on previous
research [4,127,128]. Furthermore, stress is also known to exacerbate disease-related symptoms such as the motor symptoms of
patients with tic disorders or PD [114,129,130]. Preliminary evidence indicates the beneﬁcial effects of TMS on motor performance
as well [131,132].
Recently, the possibility of COVID-19-associated nervous system
diseases has also been clinically proven by detecting the ribonucleic
acid (RNA) of the virus in the cerebrospinal ﬂuid of a patient [133].
Neurological symptoms such as impaired consciousness, headache,
dizziness and taste or smell impairment are not uncommon [134].
Therefore, the long-term follow-up and monitoring of severe cases
of COVID-19 in terms of neurological symptoms is highly advised
[135]. Through the enhancement of neural plasticity, some COVID19-related neurological residual symptoms might be attenuated by
NIBS. In a rat model, TMS has been found to reduce inﬂammation
after focal brain injury [136] and to decrease the production of

M. Bikson et al. / Brain Stimulation 13 (2020) 1124e1149

proinﬂammatory cytokines in patients with PD [137]. Moreover,
patients with disorders of consciousness have shown neurobehavioral and electrophysiological gains after multiple sessions of
NIBS [138e140]. Therefore, anti-inﬂammatory potential and
neurological utilization of NIBS might also be investigated.
Finally, there may be opportunities to apply NIBS in the broader
context of changing medical protocols. This could span changing
methods and access to prescribed medications (e.g. ability to diagnose, monitor for adverse events) as well as any consideration of
unexpected interactions between drugs (e.g. psychotropics) and
antiviral medication. A general feature of NIBS is its non-drug nonsystematic application nature, non-addictive nature, and ability to
terminate or adjust dose (in clinic or remote for home-based
treatment) and vice versa. Clearly, there is potential for NIBS as a
unique treatment tool in the ﬁght against the medical and psychological after-effects of the COVID-19 outbreak.
Conclusion
The COVID-19 pandemic, just like all crises, has yielded challenges for researchers, clinicians, participants and patients, but also
lessons to learn from and new opportunities to pursue. By synthesizing the experiences of experts from all over the world, this
consensus paper establishes practical recommendations to follow
in operationalizing NIBS during COVID-19 pandemic, mitigating the
risk of infections, and in preparing the NIBS community for any
future epidemic/pandemic. Indeed, as we emerge from the current
pandemic, the number of people who require innovative treatments such as NIBS due to direct and indirect effects of COVID-19
onto the brain and mental health will signiﬁcantly increase. This
burden on the health care systems mandates broader investigation
and adoption of therapeutic solutions such as the use of NIBS. For
NIBS laboratories and clinics to contribute to the ease the burden of
the pandemic, it is necessary to re-establish operation with prudent
protocol modiﬁcations as soon as possible.
Maintaining ongoing and restarting operations at NIBS clinics
and research institutions across the world requires accommodation
to strict measures (namely social/physical distancing) introduced
due to the COVID-19 outbreak The suddenness and severity of
initial restrictions resulted in signiﬁcant disruptions to ongoing
clinical treatment and trials (spanning suspension recruitment of
participants, interruption of ongoing treatment, to complete suspension of in-person activities). The degree of interruption varied;
for example, in-person non-clinical (non-essential) work was
largely halted while remote-tDCS clinical activity continued.
Interruption of ongoing trials is compounded by overall operational
and programmatic uncertainties e.g. the situation of students and
early career scientists, ﬁnancial concerns. The overarching concern
is when and how speciﬁc clinical and laboratory work can be
resumed and what precautions are to be adopted. This document
provides guidelines for maintaining and resuming NIBS operations.
We distinguish three phases of procedural responses (immediate COVID-19 impact, current practices, and future preparation),
with current reactions of the NIBS community to the COVID-19
pandemic largely in early phases with reactions aiming to limit
disruption to ongoing protocols. However, streamlining and
expanding NIBS services is now ongoing.
Based on the analysis of international experts with domain
relevant expertise covering NIBS technology, clinical services, and
human trials, we formed recommendations to ensure the safety of
participants, researchers and staff members during the reestablishment of access to NIBS clinical services and research operations. Apart from the obvious preparations (e.g. sanitization and
social distancing protocols and remote data acquisition where
possible), recommendations are also made regarding protocol
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optimization, methodological good practices, the support of all
stakeholders including early career scientists. To foster this process,
a checklist is also provided in the article. Mitigation plans to reduce
the risk of infection for subjects/participants and research/clinical
staff are preeminent but should be based on the applicable national
and institutional guidance and scientiﬁc understanding to avoid
being misdirected or unduly burdensome. Recommendation on
precautions are also discussed considering pediatric research, older
adults, patients with addiction, stroke, MS or other chronic
neurodegenerative/inﬂammatory disorders.
As explicated through this document, appropriate safety protocols are crucial to provide NIBS for those who require mental
health care regardless of, and also aggravated by, the outbreak.
With well-coordinated and strategic responses, the NIBS community can play an expanding role in managing the burden related to
the COVID-19 pandemic while continuing to generate clinical and
scientiﬁc regarding the efﬁcacy and underlying mechanisms of
NIBS. As we have discussed above, expanding clinical trials with
telemedicine-based NIBS are of high impact in the current situation
and considering future outbreaks and longstanding need for vigilance. Since tES devices are more easily transportable and simple to
use, the remote application of tES is more supported in contrast to
TMS. Guidelines [46,56] and empirical experience [140e142]
regarding the at-home applications of tDCS are available. Experiences gained through this process as well as new perspectives
gathered during the challenging era of COVID-19 might delineate
new research and therapeutic goals and become invaluable when
preparing for future outbreaks.
The interest in telemedicine-based solutions has especially
increased among the NIBS community [61] and the experiences
gained from such studies conducted during the outbreak will be
broadly valuable. Generally, remote NIBS solutions extend the
availability of neuromodulation, and can reduce costs of increasing
the trial sample sizes and treatment duration. The adaptation
process of some in-clinic TMS solutions that sustained operation
during the pandemic and protocols to reduce contact is addressed.
The NIBS community has faced varied degrees of disruption that
has broadly challenged laboratories and clinics across the globe. By
working around evolving restrictions and uncertainties, strategic
(and not unduly burdensome) implementation of applicable safety
procedures, and adaptation of protocol components to limit inperson activities, access to NIBS must be continued and reestablished rapidly. In this article, approaches and practical recommendations have been provided. Indeed, if further outbreaks
arise, the NIBS community will be better prepared for them.
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